IFNB1 and progressive multifocal leukoencephalopathy: Natalizumab [19, 20] is more efficacious than interferon beta and glatiramer acetate [21, 22], but has a complex safety profile due to the risk of progressive multifocal leukoencephalopathy (PML) [19, 20].